Last updated: July 29, 2026
Desoxyn (methamphetamine hydrochloride) clinical trials update, market analysis, and projection
Executive summary: Desoxyn (methamphetamine HCl) remains a legacy CNS stimulant marketed for ADHD and exogenous obesity. Public clinical-trials signals for new Desoxyn-specific registration studies are limited, with most recent development activity in the broader methamphetamine and ADHD stimulant class rather than new Desoxyn entrants. Market growth is constrained by generic availability of methamphetamine HCl tablets, ongoing payer scrutiny of schedule II stimulants, and substitution to other ADHD therapies with larger evidence bases and broader payer coverage. Near-to-midterm revenue projection is therefore modest and largely determined by maintaining label access and adherence to stimulant stewardship, not by major trial-driven expansions.
What is Desoxyn (methamphetamine hydrochloride) and what is its current FDA status?
Quick answer: Desoxyn is FDA-approved as methamphetamine HCl tablets for (1) ADHD and (2) exogenous obesity (short-term adjunct). As a generic-competitive, schedule II product, it operates under constrained demand drivers rather than being in a growth phase driven by new clinical evidence.
Label indications and practical market implications
- ADHD: symptomatic treatment in children and adults meeting typical stimulant-label criteria.
- Exogenous obesity: short-term adjunct in a regimen of caloric restriction and other measures.
Regulatory context that shapes commercial trajectory
- Methamphetamine HCl is a controlled substance (schedule II), which affects:
- pharmacy dispensing logistics
- inventory volatility
- payer authorization patterns (coverage policy + prior authorization)
- prescriber utilization patterns (particularly for obesity indications)
What clinical trials have been reported for Desoxyn specifically in the last 5 years?
Quick answer: No clearly identifiable, high-signal, late-stage Desoxyn-specific (methamphetamine HCl) trials with meaningful enrollment milestones have been consistently reported in the public domain in the last five years. Reported activity tends to be (a) class-level stimulant studies, (b) academic or comparative research, or (c) trials using methamphetamine derivatives for non-ADHD indications under different regulatory endpoints.
What typically drives “new evidence” for legacy stimulants
For marketed schedule II drugs, meaningful activity often concentrates in:
- pharmacokinetic (PK) comparability studies
- formulation or bioavailability work (where relevant)
- safety surveillance or pragmatic real-world evidence studies
- label-expansion pathways that usually face high clinical and regulatory bar
Key takeaway for planning
Given the limited public evidence of new Desoxyn registration trials, the most actionable near-term commercial lever is formulary access and contracting, not trial-readout-dependent expansion.
What patents protect Desoxyn and how do they affect generic competition?
Quick answer: The Desoxyn brand competes against generic methamphetamine HCl tablets. Brand pricing and profitability depend on remaining differentiation through contracting, supply reliability, and prescriber preference rather than exclusionary patent barriers against new entrants for the core dosage form.
Patent estate dynamics for legacy methamphetamine products
Even without listing a complete, validated patent-by-patent chart (which requires Orange Book and assignment-by-assignment verification), market structure indicates:
- generics already exist for methamphetamine HCl tablets
- brand exclusivity does not appear to block generic substitution at the national scale
Commercial implication
- Any “patent strength” today is less about preventing generics and more about protecting:
- specific product configurations
- packaging/NDC continuity
- manufacturing processes (if proprietary)
- any incremental formulation or method-of-use coverage (if present)
What is the Orange Book status of Desoxyn (methamphetamine HCl)?
Quick answer: Desoxyn is an FDA-approved product that has historically been listed with associated regulatory documentation, but the current competitive landscape is dominated by generic substitution, which indicates limited remaining brand-level exclusivity leverage for core methamphetamine HCl tablet therapy.
How Orange Book status typically translates into market behavior
- If the Orange Book shows multiple generic listings with therapeutic equivalence, brand volume is pressured.
- If any brand still holds listed exclusivity for specific patents, it tends to:
- preserve a niche
- reduce the speed of some generics
- support payer-specific contracting advantages
In practice for Desoxyn, brand differentiation appears mostly contract-driven.
When does Desoxyn lose exclusivity and what are the generic entry risks?
Quick answer: Generic entry risk is not a near-term threat because generics for methamphetamine HCl tablets already exist. The risk that matters commercially is switching pressure from:
- pharmacy benefit manager (PBM) formularies
- net price revisions for schedule II generics
- stocking and shortage dynamics that can alter brand vs. generic relative availability
Generic entry risk that can still affect revenue
Even with generics already present, brand revenue can be impacted by:
- additional generic launches with better AWP-to-NADAC spreads
- new suppliers entering with aggressive rebate structures
- supply shortages in brand or specific generic plants
How does Desoxyn compare with other ADHD stimulants and what does that do to demand?
Quick answer: Desoxyn competes with a broader ADHD stimulant ecosystem with stronger growth tailwinds from:
- extended-release methylphenidates
- extended-release amphetamine-based therapies
- non-stimulant and adjunct ADHD options
These competitors often win on payer preferences and patient adherence, which reduces the incremental market share available to older immediate-release therapies.
Competitive set shaping substitution
Desoxyn is typically assessed against:
- methylphenidate ER and IR products
- amphetamine ER products
- lisdexamfetamine-based regimens
- non-stimulants (atomoxetine, guanfacine ER, clonidine ER) depending on payer coverage
Market behavior observed for stimulant classes
- Patients and prescribers favor lower dosing complexity and smoother coverage profiles.
- Payers often prefer products with:
- predictable utilization
- established prior authorization criteria
- favorable rebate economics
What formulation and manufacturing/IP barriers matter for Desoxyn?
Quick answer: For a legacy immediate-release tablet, barriers are primarily manufacturing scale, regulatory compliance, and supply continuity, not novel drug substance discovery. The strongest barriers are typically:
- quality system execution and batch consistency
- schedule II distribution control
- line-clearance and controlled-substance logistics
Practical implications for brand vs. generic economics
- If the brand can secure continuity of supply during generic disruptions, it can temporarily gain share.
- If contracts push dispensing toward specific generic SKUs, brand share compresses.
What market size and demand drivers should be used for Desoxyn projections?
Quick answer: Desoxyn demand is driven by the treated ADHD and obesity populations that remain on methamphetamine HCl specifically, net of switching to other stimulants and payer constraints. Without new trial-driven label expansions, projections should be anchored to:
- ADHD diagnosis prevalence and stimulant utilization patterns
- formulary access and net pricing
- substitution rates toward preferred extended-release products
- controlled-substance supply stability
Demand drivers (positive)
- continuity of access for patients already stabilized on methamphetamine HCl
- shortage-driven temporary substitution dynamics (brand supply wins)
- clinician familiarity in specific patient cohorts
Demand constraints (negative)
- immediate-release dosing burden vs. ER alternatives
- payer formulary pressure toward preferred stimulants
- sensitivity to schedule II policy scrutiny
- obesity indication is typically smaller and more payer-restricted than ADHD
Desoxyn revenue projection: what scenario range is most defensible?
Quick answer: A reasonable planning range for Desoxyn over the next several years is flat to low-single-digit growth, with potential volatility tied to supply and contracting rather than clinical expansion. The upside case requires sustained payer access or supply advantage; the downside case comes from accelerated switching to preferred stimulant SKUs and tighter rebate structures.
Scenario framework (planning range)
- Base case (most likely): flat revenue with modest growth from stable prescribing and limited net price erosion.
- Upside case: brief share gains from generic supply disruption or favorable PBM contracting.
- Downside case: continued formulary displacement by ER stimulants and price compression for methamphetamine tablet SKUs.
What to monitor each quarter
- PBM formulary updates and contract renewals for schedule II stimulants
- inventory signals and controlled-substance distribution constraints
- prescribing trend shifts from immediate-release methamphetamine to ER options
- any public safety or policy changes affecting stimulant dispensing
What clinical, regulatory, and policy risks affect Desoxyn adoption?
Quick answer: The risk profile is dominated by schedule II policy enforcement, prescriber compliance expectations, and payer controls rather than standard FDA development risks.
Key risk channels
- state-level controlled-substance monitoring intensity
- payer prior authorization criteria tightening
- prescriber risk management practices for CNS stimulants
- public scrutiny of methamphetamine-related misuse narratives (even when the product is prescription-only)
What litigation or settlement activity could affect Desoxyn availability or marketing?
Quick answer: Any litigation that affects availability or distribution typically appears through:
- controlled-substance distribution disputes
- product liability claims
- patent litigation involving generics
A complete, actionable litigation map requires verified docket-by-docket confirmation. The commercial thesis for Desoxyn should not assume litigation-driven exclusivity restoration because generics already exist.
How strong is the patent estate for Desoxyn (and what is the practical takeaway)?
Quick answer: Practically, the patent estate strength for blocking new generic entry is limited because generic methamphetamine HCl tablets already compete. The practical “strength” question is whether any brand-level protection still supports:
- specific NDC continuity
- formulation-specific benefits
- manufacturing know-how differentiation
Commercial outcomes are therefore more sensitive to contracting and supply continuity than to the ability to exclude generics.
Which companies sell methamphetamine HCl tablets and how does that shape Desoxyn pricing power?
Quick answer: The market includes brand and multiple generic suppliers. Pricing power for Desoxyn depends on:
- net pricing under payer contracts
- rebate competitiveness vs. generic NADAC/AWP dynamics
- availability during generic shortages
Pricing power reality for legacy stimulants
With generics established, the brand’s pricing power is usually narrow and episodic.
Key Takeaways
- Desoxyn remains a legacy schedule II stimulant with ADHD and exogenous obesity indications, but clinical-trial signals for new Desoxyn-specific registration studies appear limited in public reporting.
- Commercial trajectory is constrained by generic substitution of methamphetamine HCl tablets and substitution to other stimulant classes with ER profiles and stronger payer preference.
- Near- to midterm revenue projections should be modeled as flat to low-single-digit growth, with volatility driven by PBM contracting, formulary placement, and controlled-substance supply continuity.
- The most actionable levers are commercial execution and access, not trial-led label expansion.
FAQs
- Is Desoxyn being discontinued or is it expected to remain on the market?
- How does Medicaid prior authorization for ADHD stimulants affect Desoxyn dispensing rates?
- What are the main differences between Desoxyn and lisdexamfetamine or mixed amphetamine salts for ADHD?
- Do Desoxyn shortages historically shift demand to specific generic methamphetamine HCl manufacturers?
- Are there any ongoing methamphetamine HCl formulation or PK studies that could affect generic competitiveness?
References (APA)
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Desoxyn (methamphetamine hydrochloride) label and approval information. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
